Jeffrey Sparling, MD
Interventional Cardiology · Oklahoma City, OKNPI 1679535223
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $160,662 of the $230,932 with a category attached, or 69.6%. Medtronic accounts for 91.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $73,763 and has fallen 59.7% since, to $29,729 in 2025. Among interventional cardiology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 823 payments — averaging $280.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$211K
- Edwards Lifesciences$6K
- Abbott$4K
- Boston Scientific$4K
- Shockwave Medical, Inc$1K
- Abiomed$1K
- plus $3K from 23 others
Across 65 payments — averaging $2305.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$87K
- CSL Behring$63K
What the payments were for
- Speaking & faculty fees$160,66270%
- Travel & lodging$42,79919%
- Food & beverage$27,47112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 410 | $211,090 |
| Edwards Lifesciences | 60 | $6,357 |
| Abbott | 52 | $4,189 |
| Boston Scientific | 141 | $3,952 |
| Shockwave Medical, Inc | 17 | $1,103 |
| Abiomed | 19 | $1,023 |
| Philips North America LLC | 18 | $552 |
| Heartflow, Inc. | 8 | $496 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $424 |
| Atricure, Inc. | 4 | $346 |
| Penumbra, Inc. | 5 | $325 |
| E.r. Squibb & Sons, L.L.C. | 23 | $237 |
| Ascensia Diabetes Care US Inc. | 1 | $128 |
| Cordis US CORP. | 1 | $126 |
| Novartis | 5 | $97 |
| Esperion Therapeutics, Inc. | 5 | $97 |
| Amgen | 6 | $95 |
| Pfizer | 4 | $59 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Johnson & Johnson | 2 | $28 |
| Terumo Medical Corporation | 2 | $27 |
| Surmodics, Inc. | 2 | $26 |
| Boehringer Ingelheim | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$107,351
- CoreValve Evolut$92,705
- APOLLOTM$1,697
- EVOQUE$1,331
- TRICLIP$984
- Watchman$473
- MitraClip$430
- Impella$416
- 3F$415
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$279
- ABSOLUTE PRO$271
- Supera peripheral stent system$271
- Indigo System$270
- Absorb GT1$268
- GENERAL - THERAPIES$256
- WATCHMAN Access System$252
- LOTUS EDGE$248
- Vascular Lithotripsy$246
- Mosaic$195
- Onyx$174
How this compares
$230,932 in reported general payments places this provider in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 415 | $435,324 |
| FarxigaDapagliflozin Propanediol | 156 | $150,648 |
| XareltoRivaroxaban | 145 | $128,891 |
| EntrestoSacubitril/Valsartan | 112 | $116,997 |
| Repatha SureclickEvolocumab | 104 | $78,486 |
| NexletolBempedoic Acid | 46 | $25,685 |
| VascepaIcosapent Ethyl | 33 | $19,638 |
| BrilintaTicagrelor | 29 | $16,951 |
| MultaqDronedarone Hcl | 13 | $9,912 |
| Metoprolol Succinate | 477 | $7,143 |
| CorlanorIvabradine Hcl | 12 | $6,904 |
| JardianceEmpagliflozin | 12 | $5,825 |
| Atorvastatin Calcium | 390 | $4,995 |
| Ranolazine ErRanolazine | 37 | $4,210 |
| Losartan Potassium | 277 | $3,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $435,324415 claims |
| AstraZenecaFarxiga, Brilinta | $15 | $167,599185 claims |
| Johnson & JohnsonXarelto | $28 | $128,891145 claims |
| NovartisEntresto | $97 | $116,997112 claims |
| Esperion Therapeutics, Inc.Nexletol | $97 | $25,68546 claims |
| Sanofi-aventis U.S. LLCMultaq | $13 | $9,91213 claims |
| AmgenCorlanor | $95 | $6,90412 claims |
| Boehringer IngelheimJardiance | $16 | $5,82512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
- Syed AliOklahoma City$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.